Our offerings
Market Access Strategy, HTA, and Health Economics
Nordic RWE & Evidence Generation
AI & Dashboard Solutions
Policy Shaping & Life Science Consulting
Our work
The latest
Our people
Careers
Contact us
Danish Medicines Council decisions from April 2026
NICE recommends Blenrep for relapsed multiple myeloma
TLV publishes health economic assessment of Blenrep
Menu